MV130 Mucosal Vaccine Reduces COPD Exacerbations in Phase 3 Trial

Published on: July 30, 2026

A phase 3, randomized, double-blind, placebo-controlled trial found the sublingual mucosal vaccine MV130 significantly reduced the number of moderate and severe exacerbations in patients with frequent-exacerbator chronic obstructive pulmonary disease (COPD) over an 18-month study period, according to results published in the European Respiratory Journal.1

Respiratory infections remain the primary trigger of COPD exacerbations, yet no approved vaccine directly targets the pathogens responsible, leaving prevention strategies limited beyond standard maintenance therapy.1 MV130 is formulated from heat-inactivated whole-cell bacteria administered sublingually, designed to induce trained immunity, a nonspecific innate immune memory offering broad-spectrum protection beyond its bacterial antigens.1 The trial enrolled patients with a frequent-exacerbator phenotype already receiving maintenance COPD therapy, a population with limited additional preventive options.1

Luis Puente Maestú, MD, PhD, Chief of the Pneumology Department at the University Hospital General Gregorio Marañón, Madrid, and colleagues wrote that “As a trained immunity-based vaccine, MV130 induces long-lasting, nonspecific immunity to subsequent microbial challenges via epigenetic reprogramming of innate immune cells, thereby conferring broad-spectrum protection beyond its constituent antigens.”1

Is MV130 Efficacious in Reducing COPD Exacerbations?

The phase 3, multicenter trial randomized 198 patients across 7 hospitals in Spain 1:1 to daily sublingual MV130 (300 FTU) or placebo for 12 months, followed by 6 months of observation (NCT01842360).1 Eligible patients had 3 or more moderate exacerbations, or 2 or more with at least 1 requiring hospitalization, in the prior year.1 The primary outcome was the total number of exacerbations over the full 18-month period, assessed in both intention-to-treat (ITT, n=198) and per-protocol (PP, n = 142) populations.1

In the ITT population, MV130 reduced the median number of exacerbations to 2.0 (IQR, 1.0-3.0) versus 3.0 (IQR, 1.0-5.0) with placebo (P =.001), with 216 total exacerbations recorded in the MV130 group versus 363 with placebo.1 The exacerbation rate was 1.87 events per patient-year with MV130 versus 2.68 with placebo, a difference of 0.81 events (95% CI, 0.44-1.18; P< .001).1 By severity, MV130 reduced moderate exacerbations (IRR, 0.70; 95% CI, 0.57-0.86) and severe exacerbations (IRR, 0.51; 95% CI, 0.34-0.76), with no significant effect on mild exacerbations (IRR, 1.10; 95% CI, 0.67-1.81).1

Key Facts

What is MV130 being studied for in COPD?

MV130, a sublingual mucosal trained immunity-based vaccine, is being studied as an adjunct preventive therapy to reduce moderate and severe exacerbations in patients with frequent-exacerbator COPD; it is not an approved product.

How does MV130 work?

MV130 contains heat-inactivated whole-cell bacteria administered sublingually, designed to induce trained immunity, a form of innate immune memory conferring broad, nonspecific protection against respiratory pathogens beyond its own bacterial antigens.

What did the phase 3 MV130 COPD trial show?

MV130 significantly reduced total, moderate, and severe COPD exacerbations versus placebo over 18 months and was associated with reduced hospitalizations, antibiotic use, and improved 12-month quality-of-life scores, with an adverse event rate similar to placebo.

How Could MV130 Affect Healthcare Use and Quality of Life?

Time to first exacerbation did not differ significantly between groups over the full 18-month study period (HR, 1.26; 95% CI, 0.92-1.72; P=.14).1 When the analysis was restricted to the 6-month post-treatment follow-up period alone, time to first exacerbation was significantly delayed with MV130 (HR, 2.15; 95% CI, 1.37-3.36; P = .001), a pattern the study authors attributed to a time-dependent treatment effect.1 MV130 was also associated with reductions in antibiotic use (IRR, 0.62; 95% CI, 0.59-0.65), systemic corticosteroid use (IRR, 0.81; 95% CI, 0.73-0.90), hospitalizations (IRR, 0.60; 95% CI, 0.37-0.96), and emergency room visits (IRR, 0.48; 95% CI, 0.32-0.71).1

COPD Assessment Test (CAT) scores differed by 2.2 points favoring MV130 at 12 months (95% CI, -4.3 to -0.14; P = .037), exceeding the established minimum clinically important difference, though the difference was not significant at 18 months (1.5 points; 95% CI, -3.8 to 0.7).1 A total of 229 adverse events occurred in 103 participants (52%), with similar rates between MV130 (50.4%) and placebo (49.6%) groups.1 Two nonserious adverse events, urticaria in the placebo group and pruritus in the MV130 group, were assessed as possibly related to study medication; 3 deaths occurred during the trial, none considered treatment-related.1

The study authors noted a prior phase 2b trial of a targeted Haemophilus influenzae/Moraxella catarrhalis vaccine failed to reduce moderate or severe COPD exacerbations, contrasting with the broader trained-immunity mechanism reported for MV130.2 Because its mechanism differs from other recently studied COPD exacerbation therapies, including the interleukin-4/13 inhibitor dupilumab, the study authors suggested MV130 could offer a complementary approach alongside existing treatments.1

References

Maestu LP, Rubio MC, Benedetti P, et al. Prevention of COPD exacerbations with a mucosal trained immunity-based vaccine (MV130): a randomised phase 3 trial. Eur Respir J. 2026; in press. doi:10.1183/13993003.00027-2026
Andreas S, Testa M, Boyer L, et al. Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial. Lancet Respir Med. 2022;10(5):435-446.